Neuromyelitis optica spectrum disorder (NMOSD): cross-border specialty drug access for international patients

Quick orientation

NMOSD affects an estimated 0.5 to 4 per 100,000 people globally, with higher prevalence in some Asian and African populations.

Typical age of onset. Most commonly between ages 30 and 50. Female predominance is approximately 9 to 1 in seropositive disease.

Severity tiers. Severity ranges from monophasic disease to relapsing forms with significant cumulative disability.

Why specialty drugs for Neuromyelitis optica spectrum disorder (NMOSD) are hard to access internationally

Three monoclonal antibodies are FDA-approved for AQP4-IgG seropositive NMOSD: eculizumab, satralizumab, and inebilizumab. Newer rituximab and complement inhibitor options are emerging. International registration varies.

Treatments approved by the FDA

• Soliris (eculizumab) — FDA approval: 2007 (NMOSD 2019). Mechanism: Complement C5 inhibitor. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 500,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt.
• Rystiggo (rozanolixizumab) — FDA approval: 2023. Mechanism: FcRn antagonist (myasthenia gravis label; adjacent autoimmune pathway). Route: Subcutaneous infusion weekly cycles. US WAC ballpark: Approximately USD 350,000 per year. Country pricing: Jordan · Bahrain · Lebanon.

Cross-border pathways used for Neuromyelitis optica spectrum disorder (NMOSD)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Expanded Access Program (EAP)
• Compassionate Use

What your physician needs to know

• Confirm AQP4-IgG or MOG-IgG status.
• Document relapse history and current disability.
• Meningococcal vaccination is required before initiating complement inhibitor therapy.
• Neurologist with NMOSD experience co-manages.
• Pregnancy planning where relevant.

Common questions

Which biologic is right for me?

Choice depends on antibody status, relapse history, prior therapy, and preferences. Your neurologist decides.

Why do I need a meningococcal vaccine?

Complement inhibition increases risk of meningococcal infection. Vaccination is required before initiation.

Are these drugs available locally?

Some are widely registered; others are narrower. We confirm by destination.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Neurologist's prescription, antibody status, relapse history, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Neuromyelitis optica spectrum disorder (NMOSD), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Neuromyelitis optica spectrum disorder (NMOSD)

Reserved for you.